A Phase III, Multiple-center, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy, Immunogenicity, and Safety of an Adjuvanted, Inactivated Enterovirus 71 (EV71) Vaccine in Healthy Infants and Children
Latest Information Update: 16 Aug 2023
At a glance
- Drugs Enterovirus A vaccine (Primary) ; Aluminium hydroxide
- Indications Enterovirus infections
- Focus Pharmacodynamics; Registrational; Therapeutic Use
- Sponsors Enimmune Corporation
- 09 Aug 2023 Planned End Date changed from 21 May 2024 to 31 Dec 2024.
- 09 Aug 2023 Planned primary completion date changed from 30 Jun 2022 to 30 Jun 2024.
- 15 Nov 2021 Planned End Date changed from 21 May 2023 to 21 May 2024.